MOLN News and Press, Molecular Partners AG From 12/07/25

Poster outlines clinical benefit with acceptable safety profile across 9 tested dosing regimens Accelerated step-up dosing and higher dosing frequency is feasible and results in increased exposure Six of eight responders presented with low bone marrow blast counts at basel...

2025-11-12 19:41:40 ET Molecular Partners AG (MOLN) Discusses First Human Imaging Data and Clinical Plans for MP0712 Radiotherapy Program November 12, 2025 10:00 AM EST... Read the full article on Seeking Alpha For further details see: Molecular Partners AG (MOLN) Discusses ...

Case study with first patient images of half-life engineered MP0712 from compassionate care use show specific uptake in primary tumors and metastatic lesions MP0712 Radio-DARPin leverages rapid internalization & replenishment of DLL3 to achieve high accumulation in tumor cells ...

ZURICH-SCHLIEREN, Switzerland and CONCORD, Mass., Nov. 03, 2025 (GLOBE NEWSWIRE) -- Ad hoc announcement pursuant to Art. 53 LR Molecular Partners AG (SIX: MOLN; NASDAQ: MOLN), a clinical-stage biotech company developing a new class of custom-built protein drugs known as DARPin therapeutic...

Poster presentation outlines potential of CD3 Switch-DARPin T cell engager (TCE) using an AND-gate to overcome limitations of other TCEs Demonstrated selective T cell cytotoxicity against cells co-expressing tumor-associated antigens MSLN and EpCAM Induced significant ...

IND application filed for MP0712, the Company’s lead Radio-DARPin candidate targeting DLL3 and co-developed with Orano Med, with Phase 1 initiation expected before year end 2025 First patient images from MP0712 compassionate care program to be presented at TRP in November; addi...

California Water Service Group (CWT) is expected to report $1.2 for Q3 2025 Gilead Sciences Inc. (GILD) is expected to report $2.15 for Q3 2025 Schneider National Inc. (SNDR) is expected to report $0.21 for Q3 2025 Fidus Investment Corporation (FDUS) is expected to report $0.5 for Q3 ...

MP0533 data presented at European Hematology Association (EHA) highlights improved response rates and antitumor activity in low disease burden patients; additional data under amended dosing scheme expected in Q4 2025 IND filing on first radio-DARPin program MP0712 and initiation of Phase ...

Adamas One Corp. (JEWL) is expected to report for quarter end 2025-03-31 Avidbank Holdings Inc. (AVBH) is expected to report $0.75 for Q2 2025 Vapotherm Inc. (VAPO) is expected to report for quarter end 2025-06-30 Intesa Sanpaolo Spa ADR (ISNPY) is expected to report $0.94 for Q2 2025...

Molecular Partners AG (MOLN) is expected to report $-0.53 for Q2 2025